Rocket-miR, a translational launchpad for miRNA-based antimicrobial drug development

mSystems. 2023 Dec 21;8(6):e0065323. doi: 10.1128/msystems.00653-23. Epub 2023 Nov 17.

Abstract

Antimicrobial-resistant infections contribute to millions of deaths worldwide every year. In particular, the group of bacteria collectively known as ESKAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter sp.) pathogens are of considerable medical concern due to their virulence and exceptional ability to develop antibiotic resistance. New kinds of antimicrobial therapies are urgently needed to treat patients for whom existing antibiotics are ineffective. The Rocket-miR application predicts targets of human miRNAs in bacterial and fungal pathogens, rapidly identifying candidate miRNA-based antimicrobials. The application's target audience are microbiologists that have the laboratory resources to test the application's predictions. The Rocket-miR application currently supports 24 recognized human pathogens that are relevant to numerous diseases including cystic fibrosis, chronic obstructive pulmonary disease (COPD), urinary tract infections, and pneumonia. Furthermore, the application code was designed to be easily extendible to other human pathogens that commonly cause hospital-acquired infections.

Keywords: CF pathogens; ESKAPE pathogens; antimicrobial agents; bioinformatics; cystic fibrosis; host-pathogen interactions; miRNA.

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Infective Agents* / pharmacology
  • Enterobacter
  • Humans
  • MicroRNAs* / genetics
  • Staphylococcus aureus

Substances

  • MicroRNAs
  • Anti-Bacterial Agents
  • Anti-Infective Agents